EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly

Sabina Ruiz iD, Joan Gil iD, Betina Biagetti, Eva Venegas, Rosa Cámara, Rogelio Garcia-Centeno, María-Ángeles Gálvez, Antonio Picó, Silvia Maraver, Inmaculada González, Pablo Abellán, Pablo Trincado und 12 weitere

Clinical Endocrinology · 2023

DOI: 10.1111/cen.14946 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Endocrinology, 2023. Verfasst von Sabina Ruiz und 23 weiteren Autor:innen. Beteiligte Einrichtung: Germans Trias i i Pujol Research Institute and Hospital, Universitat Autònoma de Barcelona, Badalona, Spain. Hauptthemen laut MEDLINE: Acromegaly, Adenoma, Human Growth Hormone. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Hyperintensity signal in T2‐weighted magnetic resonance imaging (MRI) has been related to better therapeutic response during pasireotide treatment in acromegaly. The aim of the study was to evaluate T2 MRI signal intensity and its relation with pasireotide therapeutic effectiveness in real‐life clinical practice. Design, Patients and Measurements Retrospective multicentre study including acromegaly patients treated with pasireotide. Adenoma T2‐weighted MRI signal at diagnosis was qualitatively classified as iso‐hyperintense or hypointense. Insulin‐like growth factor (IGF‐I), growth hormone (GH) and tumour volume reduction were assessed after 6 and 12 months of treatment and its effectiveness evaluated according to baseline MRI signal. Hormonal response was considered ‘complete’ when normalization of IGF‐I levels was achieved. Significant tumour shrinkage was defined as a volume reduction of ≥25% from baseline.

Results

Eighty‐one patients were included (48% women, 50 ± 1.5 years); 93% had previously received somatostatin receptor ligands (SRLs) treatment. MRI signal was hypointense in 25 (31%) and hyperintense in 56 (69%) cases. At 12 months of follow‐up, 42/73 cases (58%) showed normalization of IGF‐I and 37% both GH and IGF‐I. MRI signal intensity was not associated with hormonal control. 19/51 cases (37%) presented a significant tumour volume shrinkage, 16 (41%) from the hyperintense group and 3 (25%) from the hypointense.

Conclusions

T2‐signal hyperintensity was more frequently observed in pasireotide treated patients. Almost 60% of SRLs resistant patients showed a complete normalization of IGF‐I after 1 year of pasireotide treatment, regardless of the MRI signal. There was also no difference in the percentage tumour shrinkage over basal residual volume between the two groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyAdenomaHuman Growth HormoneHumansFemaleMaleInsulin-Like Growth Factor IMagnetic Resonance ImagingTreatment OutcomeOctreotideSomatostatin

Stichwörter der Autor:innen

IGF-1T2-weighted signal intensityacromegalymagnetic resonance imagingpasireotidesomatostatin receptor ligands

Substanzen

Insulin-Like Growth Factor IHuman Growth HormoneOctreotidepasireotideSomatostatin

Autor:innen und Institutionen

  • Germans Trias i i Pujol Research Institute and Hospital, Universitat Autònoma de Barcelona, Badalona, Spain.
  • Servei d'Endocrinología i Nutrició, Hospital Universitari Vall d'Hebrón, Barcelona, Spain.
  • Servicio de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Servicio de Endocrinología y Nutrición, Hospital Universitario La Fe, Valencia, Spain.
  • Servicio de Endocrinología y Nutrición, Hospital Universitario Gregorio Marañón, Madrid, Spain.
  • Servicio de Endocrinología y Nutrición, Hospital Universitario Reina Sofía, Córdoba, Spain.

ORCID-Profile: Sabina Ruiz, Joan Gil, Ignacio Bernabeu

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Ruiz, S., Gil, J., Biagetti, B., Venegas, E., Cámara, R., Garcia-Centeno, R., Gálvez, M. Á., Picó, A., Maraver, S., González, I., Abellán, P., Trincado, P., Herrera, M., Olvera, P., Xifra, G., Bernabeu, I., Serra-Soler, G., Azriel, S., García, L., …, & Puig-Domingo, M. (2023). Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly. Clinical Endocrinology. https://doi.org/10.1111/cen.14946

Vancouver

Ruiz S, Gil J, Biagetti B, Venegas E, Cámara R, Garcia-Centeno R, et al. Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly. Clinical Endocrinology. 2023. doi:10.1111/cen.14946

BibTeX
@article{Ruiz2023,
  author = {Ruiz, Sabina and Gil, Joan and Biagetti, Betina and Venegas, Eva and Cámara, Rosa and Garcia-Centeno, Rogelio and Gálvez, María-Ángeles and Picó, Antonio and Maraver, Silvia and González, Inmaculada and Abellán, Pablo and Trincado, Pablo and Herrera, Mayte and Olvera, Pilar and Xifra, Gemma and Bernabeu, Ignacio and Serra-Soler, Guillermo and Azriel, Sharona and García, Lourdes and Carvalho, Davide and Jordà, Mireia and Valassi, Elena and Puig, Josep and Puig-Domingo, Manel},
  title = {Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly},
  journal = {Clinical Endocrinology},
  year = {2023},
  doi = {10.1111/cen.14946}
}
Kostenlos starten →